Consistently, Gef inhibits cell growth in PC-9 NSCLC cells with EGFR mutation, with a much higher potency than that in A549 and H226 NSCLC cells with wild type EGFR (Sugita et al., 2015). Here, EGFR is linked to non-small cell lung carcinoma.